Search This Blog

Thursday, October 27, 2022

Teladoc shares jump as upbeat results allay fears over mental health business

 Teladoc Health TDOC.N shares surged 10% in premarket trading on Thursday after the largest listed U.S. telehealth firm onboarded more members than it expected, allaying fears of inflation hitting its consumer-focused mental health unit.

The company, which counts Cathie Wood's Ark Investment as its largest shareholder, has been increasingly reliant on its BetterHelp mental health unit, even as analysts have raised concerns over the impact on the segment as inflation-hit consumers cut spending.

Teladoc shares have fallen more than 70% so far this year after losing over half their value last year. This is in sharp contrast to 2020 when the stock more than doubled in value on a pandemic-driven boost.

"Teladoc isn’t out of the woods yet," said Citigroup analyst Daniel Grosslight. But the solid results and the better-than-feared forecast cut show that "a clear path forward is beginning to emerge," Grosslight said in a client note.

The company cut the upper end of its full-year adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) forecast to $250 million from $265 million. The midpoint of the $240 million to $250 million forecast range was still above consensus estimates of $234 million.

At least five analysts cut their price targets on Teladoc after it tightened forecast but shares were up 9.01% at $29.15 before the bell after rising more than 10%.

U.S. paid memberships in the quarter rose nearly 10% to 57.8 million, above Teladoc's own expectations of between 55.5 to 56.5 million members.

While Teladoc remains one of the largest telehealth firms, competition is heating up, with Amazon.com Inc AMZN.O in July agreeing to buy primary care provider One Medical ONEM.O for $3.49 billion, expanding the e-commerce giant's virtual healthcare presence.

https://www.nasdaq.com/articles/teladoc-shares-jump-as-upbeat-results-allay-fears-over-mental-health-business

Labcorp's stock falls after COVID-19 test sales decline in third quarter

 Shares of Labcorp tumbled in premarket trading on Thursday after the diagnostics company said revenue in the third quarter of 2022 came in lower than expected as fewer people got PCR or antigen tests for COVID-19. Labcorp had earnings of $352.8 million, or $3.90 per share, in the third quarter of 2022, down from $587.3 million, or $6.05 per share, in the same quarter a year ago. Adjusted earnings per share were $4.68, against a FactSet consensus of $4.09. The company's revenue was $3.6 billion for the quarter. That's down from $4.0 billion in revenue in the third quarter of 2021. The FactSet consensus was $3.9 billion. Labcorp narrowed its guidance for adjusted EPS for the year, saying it now expects $19.25 to $20.25. The previous guidance was $19.00 to $21.25. The company's stock has declined 26.8% this year, while the broader S&P 500 is down 19.6%.

https://www.morningstar.com/news/marketwatch/20221027399/labcorps-stock-falls-4-after-covid-19-test-sales-decline-in-the-third-quarter

Amedisys cut to Market Perform by Raymond James

 From Outperform

https://finviz.com/quote.ashx?t=AMED&p=d

Kazia: POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data from an ongoing research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT.

A poster presentation by Dr Gennie Parkman and colleagues, working in the laboratory of Professor Sheri Holmen, has shown paxalisib to be active in vitro and in vivo against a range of preclinical models of metastatic melanoma, the most aggressive form of skin cancer. Dr Parkman's data suggested substantial activity for paxalisib as monotherapy, and greater activity in combination with MEK and BRAF inhibitors, two classes of drugs that are commonly used for a substantial proportion of melanoma patients.

https://finance.yahoo.com/news/kazias-paxalisib-demonstrates-positive-monotherapy-110000520.html

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne

 Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they have completed the rolling submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking priority review for vamorolonefor the treatment of Duchenne muscular dystrophy (DMD). Subject to approval, vamorolone is set to become available to patients in the U.S. in H2-2023.

https://www.biospace.com/article/releases/santhera-and-reveragen-complete-nda-submission-to-fda-for-vamorolone-in-duchenne-muscular-dystrophy/

Positive Topline Phase III Results for Genentech Vabysmo In Retinal Vein Occlusion

 

  • Vabysmo achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials
  • Vabysmo was generally well tolerated, with a safety profile consistent with previous trials
  • Vabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening retinal conditions
  • Detailed results will be presented at an upcoming medical meeting and submitted to regulatory authorities around the world

GSK Update on Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

 MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to or could not tolerate available treatments.

ContRAst-1 and ContRAst-2 met their primary endpoints of a statistically significant ACR20 (American College of Rheumatology criteria) response versus placebo at week 12 in patients with inadequate response to methotrexate (ContRAst-1) and conventional synthetic or biologic disease modifying antirheumatic drugs (DMARDs) (ContRAst-2). Data from ContRAst-3, the third trial in the program, did not demonstrate statistical significance on the primary endpoint of ACR20 response versus placebo at week 12 in patients with inadequate response to biologic DMARDs and/or Janus Kinase inhibitors.

According to GSK, assessment of efficacy and safety data from the ContRAst program is ongoing, however the limited efficacy demonstrated does not support a suitable benefit/risk profile for otilimab as a potential treatment to transform patient care for this difficult-to-treat population of RA patients. As a result, GSK has decided not to progress with regulatory submissions. GSK is planning to submit full results from the ContRAst phase III program for publication in 2023.

https://www.biospace.com/article/releases/gsk-morphosys-licensing-partner-provides-update-on-contrast-phase-iii-program-for-otilimab-in-moderate-to-severe-rheumatoid-arthritis/